Mumbai: Cadila Healthcare has filed an investigational new drug (IND) application for seeking DCGI’s authorization carrying out clinical examinations for new molecular entity - ZYH7, which is a novel drug candidate for treating dyslipidemia and metabolic troubles.

The company informed that ZYH7 had been conceptualised and formulated by its researchers from Zydus Research Centre.

The company has its internal research facility and it had freshly reasoned out pre-clinical reports on ZYH7 that have reported interesting and supporting finding which indicate a novel molecule to treat dyslipidemia and associated metabolic disorders.

While commenting on the new development, Pankaj Patel, chairman and managing director, Zydus Cadila said, “We have been building a promising pipeline of new molecular entities at the Zydus Research Centre and ZYH7 is an important step in this direction”.

Starting with its initial IND filing in 2005, the company today has four INDs in different level of clinical trials. NME - ZYH1 for treating dyslipidemia and ZYH for taking care of pain and inflammation are going through Phase II examinations, ZYH2 for caring blood sugar and the nCB-I antagonist. ZYO1 for treating obesity, are experiencing Phase I tests.

In early trading, the company’s share was hovering near Rs 308, up 0.89 per cent. Thus far, the stock has seen a high of Rs 310 and low of Rs 306.05.